Mobile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003367-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy and safety of YM672 administered orally in the treatment of painful bladder syndrome (PBS)/interstitial cystitis (IC). The primary efficacy endpoint is success, defined as ‘Moderately Improved’ or ‘Markedly Improved’ PBS/IC on the subject-rated 7-point Global Response Assessment (GRA) at the Week 12 and/or End of Treatment (ET) visit.

Critère d'inclusion

  • Interstitial Cystitis / Painful Bladder Syndrome

Liens